PRESCRIBING INFORMATION

XIFAXA® **550mg** Tablets (Rifaximin)

زِیفیکسا 550 ملی گرام ٹیبلیٹس

COMPOSITION:
Each film coated tablet contains:
Rifaximin …Brookes Specs…550mg
Mfg. Specs. Brookes

DESCRIPTION:

Xifaxa (Rifaximin) 550mg tablet contains a non-aminoglycoside semi-synthetic, nonsystemic antibiotic derived from rifamycin SV. Xifaxa (Rifaximin) 550mg tablet is a structural analog of rifampin. Xifaxa (Rifaximin) 550mg tablet acts by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase resulting in inhibition of bacterial RNA synthesis. Cross-resistance between Xifaxa (Rifaximin) 550mg tablet and other classes of antimicrobials has not been studied. Xifaxa (Rifaximin) 550mg tablet is thought to have an effect on the gastrointestinal flora. The efficacy of Xifaxa (Rifaximin) 550mg tablet taken orally two times a day was evaluated in a randomized, placebo-controlled double-blind, multi-center 6-month trial of adult subjects who were defined as being in remission (Conn score of 0 or 1) from hepatic encephalopathy (HE). Xifaxa (Rifaximin) 550mg tablet significantly reduces the risk of HE-related hospitalizations by 50% during the 6-month treatment period.

PHARMACOLOGY:
Absorption:
Xifaxa (Rifaximin) 550mg tablet plasma concentrations and exposures were low and variable. There was no evidence of accumulation of Xifaxa (Rifaximin) 550mg tablet following repeated administration.The PK of Xifaxa (Rifaximin) 550mg tablet in patients with a history of HE was evaluated after administration of Xifaxa (Rifaximin) 550mg tablet two times a day. The PK parameters were associated with a high variability and mean Xifaxa (Rifaximin) 550mg tablet exposure (AUC) in patients with a history of HE (147 ng•h/mL) was approximately 12-fold higher than that observed in healthy subjects following the same dosing regimen (12.3 ng•h/mL).

Metabolism and Excretion:
In a mass balance study, after administration of orally to healthy volunteers, of the 96.94% total recovery, 96.62% of the administered dose was recovered in feces almost exclusively as the unchanged drug and 0.32% was recovered in urine mostly as metabolites with 0.03% as the unchanged drug. This suggests that the absorbed Xifaxa (Rifaximin) 550mg tablet undergoes metabolism with minimal renal excretion of the unchanged drug. The enzymes responsible for metabolizing Xifaxa (Rifaximin) 550mg tablet are unknown.

INDICATIONS:
Label claim (Approved by FDA)
- **Hepatic Encephalopathy:** for maintenance of Remission of Hepatic encephalopathy.
- **Traveler's Diarrhea**

Off Label claim (under considration by FDA)
- **Irritable Bowel Syndrome**: 2 Trials (n>600 in each) in patients with IBS without constipation showed Xifaxa (Rifaximin) 550mg tablet more effective compared with placebo in providing adequate symptom relief (MEJM 2011;364:22-32)
- **Surgical Antibiotic Prophylaxis**
- **Diverticular disease**

DOSAGE AND ADMINISTRATION:
Label claim (Approved by FDA)
- **Hepatic Encephalopathy:** 550mg BID

Off Label claim (under considration by FDA)
- **Irritable Bowel Syndrome**: 550mg TID x 14 days
- **Surgical Antibiotic Prophylaxis:** 550mg BID for 3 days
- **Diverticular disease:** 550mg twice a day for the 7 days every month

CONTRAINDICATION:
Xifaxa (Rifaximin) 550mg tablet is contraindicated in patients with a hypersensitivity to active ingredient.

SIDE EFFECTS:
Xifaxa (Rifaximin) 550mg tablet is very well tolerated, The safety of Xifaxa (Rifaximin) 550mg tablet taken two times a day for reducing the risk of overt hepatic encephalopathy recurrence in adult patients was evaluated in a 6-month placebo-controlled clinical trial. Following adverse reactions that occurred

at an incidence ≥ 5% with Xifaxa (Rifaximin) 550mg tablet -treated subjects dizziness, fatigue, ascities, muscle spasms, pruritis, abdominal pain, abdominal distention, anemia, cough depression, insomnia, nasopharyngitis, abdominal pain upper, arthralgia, back pain, constipation, dyspnea , pyrexia and rash.

USE IN SPECIFIC POPULATIONS:
Pregnancy and Lactation:
Pregnancy Category C. There are no adequate and well controlled studies in pregnant women. Xifaxa (Rifaximin) 550mg tablet should be used during pregnancy only if the potential benefit out weighs the potential risk to the fetus. It is not known whether Xifaxa (Rifaximin) 550mg tablet is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for adverse reactions in nursing infants from Xifaxa (Rifaximin) 550mg tablet, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Pediatric Use:
The safety and effectiveness of Xifaxa (Rifaximin) 550mg tablet for HE have not been established in patients < 18 years of age.
Renal & Hepatic Insufficiency:
The pharmacokinetics of Xifaxa (Rifaximin) 550mg tablet in patients with impaired renal function has not been studied. No dosage adjustment is recommended because Xifaxa (Rifaximin) 550mg tablet is presumably acting locally. Nonetheless, caution should be exercised when Xifaxa (Rifaximin) 550mg tablet is administered to patients with severe hepatic impairment.

DRUG INTERACTIONS:
In vitro studies have shown that Xifaxa (Rifaximin) 550mg tablet did not inhibit cytochrome P450 isoenzymes. Cross-resistance between Xifaxa (Rifaximin) 550mg tablet and other classes of antimicrobials has not been studied. Xifaxa (Rifaximin) 550mg tablet is thought to have an effect on the gastrointestinal flora.

WARNINGS AND PRECAUTIONS:
Xifaxa (Rifaximin) 550mg tablet was not found to be effective in patients with diarrhea complicated by fever and/or blood in the stool or diarrhea due to pathogens other than Escherichia coli. Discontinue Xifaxa (Rifaximin) 550mg tablet if diarrhea symptoms get worse or persist more than 24-48 hours and alternative antibiotic therapy should be considered. There is increased systemic exposure in patients with severe hepatic impairment. Therefore, caution should be exercised when administering Xifaxa (Rifaximin) 550mg tablet to patients with severe hepatic impairment (Child-Pugh C). To be sold on prescription of a registered medical practitoner only.

STORAGE:
Store at temperature 15 to 30 ºC away from light and moisture.

PRESENTATION:
Xifaxa(Rifaximin)550mg tablet is available in pack of 10 tablets.

خوراک اور طریقہ استعمال:

ہیپیٹک انسیفلوپیتھی (HE) کے مریضوں میں ایک گولی صبح اور شام۔

ارّیٹیبل باؤل سنڈروم (IBS) میں ایک گولی دن میں تین بار 14 دن تک۔

اسٹوریج:

15 سے 30 ڈگری سینٹی گریڈ درجہ حرارت پر روشنی اور نمی سے بچا کر رکھیئے۔

brookes
Manufactured by:
Brookes Pharma Private Limited
58 - 59 Sector 15 Korangi Industrial Area
Karachi 74900 Pakistan.